Category
17 plain-language articles on women's hormonal health — the physiology, the compounds, and what the evidence actually shows.
17 articles
Why your cycle gets worse during stressful seasons
During the easy seasons, your cycle is mostly cooperative. Mild PMS, predictable timing, manageable flow. Then a stressful stretch hits — a job change, a family situation, a sustained period of overwork — and the cycle starts behaving differently. PMS gets harder. The luteal phase becomes treacherous. Periods get heavier or longer, or skip altogether. Ovulation pain shows up. By the time things calm down, the cycle has rewritten itself.
Endometriosis and the inflammation cycle
Endometriosis is a structural disease. Ectopic endometrial-like tissue grows where it doesn't belong — on the ovaries, the peritoneum, the bowel, occasionally further afield — and it responds to the cyclical hormonal signals that drive the uterine lining. The lesions bleed, scar, and adhere. The pain is organic. The management is surgical and medical, and that has to be said clearly before anything else.
The four shifts of perimenopause — and which ones are driven by stress
Perimenopause is often described as a single transition, but the lived experience is more like four overlapping shifts happening at once — each with its own mechanism and its own timeline. Sleep changes, mood changes, cycle changes, hot flashes, energy collapse, weight redistribution, brain fog. They don't all share the same driver, which is why a single intervention rarely addresses all of them and why women describe perimenopause as feeling like several different transitions stacked on top of each other.
PMDD and the cortisol-progesterone connection
PMDD is not bad PMS. It's a distinct, diagnosable condition where the luteal phase doesn't just feel uncomfortable — it becomes destabilizing. Mood collapses. Rage arrives without warning. Suicidal ideation can show up in women who feel completely well three days later, after the period starts. The pattern repeats month after month, and the recognition that the timeline is hormonal does nothing to soften the experience of living through it.
Uterine fibroids and the stress factor
Fibroids are extraordinarily common — by age 50, the majority of women have at least one — and they range from incidental findings on a routine ultrasound to lesions that drive heavy bleeding, anemia, and pressure symptoms that meaningfully interfere with daily life. The conversation about fibroids and stress isn't whether stress causes them; it's whether the hormonal and inflammatory environment that influences their growth velocity is partly shaped upstream. The honest answer is yes — within limits worth being precise about.
Cetrorelix in IVF — what GnRH antagonism actually controls
You're on day eight of stimulation. You've been injecting FSH every morning, watching follicles grow on the ultrasound monitor, doing the math on retrieval timing with your reproductive endocrinologist. Everything is on schedule. Then you get a call from the clinic: your LH is starting to move. The nurse's voice is calm but there's urgency underneath it — because a premature LH surge at this point, before the eggs are mature, means the follicles might ovulate on their own before retrieval can happen. It means the cycle could be compromised. It means weeks of preparation and thousands of dollars might not yield the retrieval you were planning on. This is the clinical problem that Cetrorelix was designed to solve, and it solves it by going directly to the source.
Cetrorelix in IVF — the patient experience explained
You've been doing the stimulation injections for a week. Every morning you pull the Gonal-F or Follistim out of the refrigerator, you've gotten comfortable with the needle, and the monitoring appointments have confirmed the follicles are growing. Then the clinic calls: start the cetrorelix tomorrow. You look at the package in your refrigerator — a small pre-filled syringe, different from what you've been using — and you want to understand what it is and what it's doing before you inject it.
Curcumin and the NF-kB switch in endometriosis
Inside an endometriotic stromal cell, a great deal of bad behavior funnels through a single switch. Inflammatory signals arrive, oxidative stress builds, prostaglandins accumulate — and all of it converges on a transcription factor called NF-kB, which, once released, walks into the nucleus and turns on the genes that keep the lesion inflamed, fed, and invasive. Now picture a yellow pigment from a kitchen spice slipping into that same cell and jamming the switch one step upstream. That is, in essence, what curcumin does, and it is why a compound most people associate with curry has earned a place in the serious conversation about endometriosis biology.
ENDO-205 — the first peptide designed to remove endometriosis lesions, not just quiet them
For decades the menu for endometriosis has had two items on it, and both leave the disease itself largely in place. A surgeon can excise the visible implants, and a clinician can lower estrogen — with a pill, a progestin, a GnRH analogue, or a levonorgestrel IUD — to quiet the bleeding and the pain. Neither switches off the biology that regrows the lesions, which is why recurrence is common and why so many women cycle through repeat surgeries and a rotating cast of hormonal regimens that manage symptoms without resolving the thing producing them. The lesion is treated as tissue to cut out or as estrogen to suppress. It is rarely treated as a target in its own right.
GLP-1s in perimenopause — when nothing else is working
You are eating the way you ate at thirty-five. You're training four days a week, sometimes five. You sleep reasonably well, you don't drink much, you track your food on and off and it's not dramatic. And the weight is still going in the wrong direction, or it isn't moving at all, or it's moving to your abdomen and waist in a way it never did before and no amount of core work touches it. You've been told it's stress. You've been told it's perimenopause and to just wait it out. You've been told your labs are normal. And you're standing in a body that feels like it's operating on entirely different rules than the one you've lived in for the last two decades.
N-acetylcysteine for endometriosis — the strongest non-hormonal signal
In a small Italian clinic, a group of women with ovarian endometriomas were given a simple, decades-old over-the-counter compound and asked to come back for repeat imaging. When they did, something quietly unusual showed up on the scans: a number of the cysts had not grown the way endometriomas usually do between visits, and several had shrunk. In the women who took nothing, the cysts continued along their expected trajectory. The compound was not a hormone. It was not a surgical instrument. It was N-acetylcysteine — a cysteine donor that pharmacists have stocked for years as a mucolytic and as the antidote for acetaminophen overdose. That a substance this unglamorous produced a measurable, lesion-level change in a disease defined by its stubbornness is the reason it deserves a careful look.
GLP-1 and Fertility: What's Real, and What's Just a Hashtag
Search #OzempicBaby and you will find thousands of women describing the same surprise: after years of struggling to conceive, they got pregnant within months of starting a GLP-1 medication. The stories are real. The interpretation surrounding them mostly is not. "Ozempic babies" is journalistic shorthand, not a medical phenomenon, and the gap between what people believe about these drugs and fertility and what the evidence actually supports is wide enough to be genuinely risky.
GLP-1 for PMOS: The 2026 Evidence, and Who Actually Benefits
The internet has already decided that GLP-1 drugs fix polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS). The literature is more disciplined, and more useful. Three things happened in 2026 that make this worth a careful read: the condition was formally renamed to center its metabolic core, several rigorous meta-analyses landed, and the first proper head-to-head combination trials reported. Put together, they let us answer the only question that matters for an individual woman: not "do these drugs work," but "would they work for me, and at what cost."
The Insulin Resistance Engine: Why PMOS Is a Metabolic Condition First
When polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) in 2026, the word "metabolic" moved into the name for a reason. For most women who carry this diagnosis, the engine running underneath the symptoms is not the ovary. It is insulin resistance. Understand that one mechanism and almost everything else about the condition, the irregular cycles, the stubborn weight, the acne and hair changes, the long-term risk of diabetes and heart disease, starts to make sense as a single connected system rather than a scattered list of problems.
PCOS Is Now PMOS: What the Rename Means for Your Metabolism, and Where GLP-1 Medicine Actually Fits
In May 2026, one of the most common hormonal conditions in women quietly changed its name. Polycystic ovary syndrome, the label roughly one in eight women has carried for decades, is now polyendocrine metabolic ovarian syndrome, or PMOS. The acronym moved by a single letter. What it signals is much larger.
Coming off birth control — the cycle that doesn't quite return
You stopped the pill on a Sunday. Your doctor said your cycle would return in a few weeks. Maybe a month. By month three, you had a period — one period — and then silence for another eight weeks. The acne that started showing up on your jaw looked exactly like what you had at seventeen. Your skin was oily in a way it hadn't been in years. Your hair felt different. You felt different, in a way that's hard to articulate but impossible to ignore — more reactive, more raw, cycling through moods in ways you didn't remember doing before. The pill, you realized, had been doing more than preventing pregnancy.
Vitamin D and omega-3 in endometriosis — the quiet anti-inflammatory levers
Pull the lab panel of a roomful of women with endometriosis and a pattern keeps surfacing: the 25-hydroxyvitamin D values run low, and the lowest of them cluster in the women whose disease is most advanced. It is the kind of association that is easy to dismiss as background noise — vitamin D is low in a great many conditions — until you look at what the vitamin actually does inside the tissues that endometriosis colonizes. Then the correlation starts to look less like coincidence and more like a clue. Vitamin D and the omega-3 fatty acids in fish oil are the two quietest levers in the endometriosis conversation, unglamorous next to surgery and hormones, and both turn out to act on the disease's biology in ways that are well understood at the molecular level even where the clinical proof is still arriving.